ATE139698T1 - Mittel zur behandlung chronischer ermüdungserscheinungen - Google Patents

Mittel zur behandlung chronischer ermüdungserscheinungen

Info

Publication number
ATE139698T1
ATE139698T1 AT93104487T AT93104487T ATE139698T1 AT E139698 T1 ATE139698 T1 AT E139698T1 AT 93104487 T AT93104487 T AT 93104487T AT 93104487 T AT93104487 T AT 93104487T AT E139698 T1 ATE139698 T1 AT E139698T1
Authority
AT
Austria
Prior art keywords
treatment
chronic fatigue
agents
polysaccharide
beta
Prior art date
Application number
AT93104487T
Other languages
English (en)
Inventor
Atsushi Uchida
Original Assignee
Kaken Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kaken Pharma Co Ltd filed Critical Kaken Pharma Co Ltd
Application granted granted Critical
Publication of ATE139698T1 publication Critical patent/ATE139698T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S426/00—Food or edible material: processes, compositions, and products
    • Y10S426/80—Geriatric
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S426/00—Food or edible material: processes, compositions, and products
    • Y10S426/81—Energy rations, e.g. emergency rations, survival rations

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
AT93104487T 1992-03-18 1993-03-18 Mittel zur behandlung chronischer ermüdungserscheinungen ATE139698T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP4092158A JPH05262654A (ja) 1992-03-18 1992-03-18 慢性疲労症候群治療剤

Publications (1)

Publication Number Publication Date
ATE139698T1 true ATE139698T1 (de) 1996-07-15

Family

ID=14046623

Family Applications (1)

Application Number Title Priority Date Filing Date
AT93104487T ATE139698T1 (de) 1992-03-18 1993-03-18 Mittel zur behandlung chronischer ermüdungserscheinungen

Country Status (7)

Country Link
US (1) US5424300A (de)
EP (1) EP0561408B1 (de)
JP (1) JPH05262654A (de)
KR (1) KR930019219A (de)
AT (1) ATE139698T1 (de)
CA (1) CA2091866A1 (de)
DE (1) DE69303305T2 (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2947044B2 (ja) * 1993-01-27 1999-09-13 味の素株式会社 免疫不全症候群治療の補助療法剤
US5712259A (en) * 1996-04-22 1998-01-27 Birkmayer Pharmaceuticals NADH and NADPH pharmaceuticals for treating chronic fatigue syndrome
US6929807B1 (en) 1996-08-09 2005-08-16 Mannatech, Inc. Compositions of plant carbohydrates as dietary supplements
US5990162A (en) * 1997-08-29 1999-11-23 Orphan Medical, Inc. Method for treatment of fibromyalgia and chronic fatigue syndrome
JP4510290B2 (ja) * 1998-08-25 2010-07-21 ノバルティス アーゲー 慢性疲労症候群および／または線維筋痛の処置のためのサブスタンスｐアンタゴニストの使用および慢性疲労症候群の処置のためのｎｋ−１レセプターアンタゴニストの使用
JP4931375B2 (ja) * 2005-06-23 2012-05-16 均 伊藤 抗筋肉疲労剤及び飲食品
JP7150494B2 (ja) * 2017-12-08 2022-10-11 株式会社神鋼環境ソリューション 疲労感改善剤
JP2020080659A (ja) * 2018-11-16 2020-06-04 株式会社神鋼環境ソリューション Ｑｏｌ改善剤
CN113577233B (zh) * 2021-09-17 2022-07-22 深圳市宝安纯中医治疗医院 一种治疗慢性疲劳综合征的中药制剂及其制备方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3819480A (en) * 1969-09-11 1974-06-25 R Hochschild Composition of methionine with 2-dimethylaminoethanol
JPS554305A (en) * 1978-06-13 1980-01-12 Nippon Zoki Pharmaceut Co Ltd Remedy for disease caused by stress and its preparation
US5118673A (en) * 1982-05-07 1992-06-02 Carrington Laboratories, Inc. Uses of aloe products
SE466289B (sv) * 1984-09-19 1992-01-27 James Hoffman Makrofagstimulerande komposition jaemte foerfarande foer dess framstaellning
US5013739A (en) * 1986-10-07 1991-05-07 Bernard Bihari Method of treating chronic fatigue syndrome using an opiate receptor antagonist
US5162037A (en) * 1988-04-01 1992-11-10 Whitson Laboratories, Inc. Magnetically influenced homeopathic pharmaceutical formulations, methods of their preparation and methods of their administration
US5189022A (en) * 1988-05-27 1993-02-23 The United States Of America As Represented By The Secretary Of Health And Human Services Composition for the treatment of chronic fatigue syndrome
US5126376A (en) * 1988-06-24 1992-06-30 Stephen Herman Method for treating viral infection using topical administration
US5055296A (en) * 1988-08-04 1991-10-08 Wagle Sudhakar S Method of treating chronic fatigue syndrome
CA1328074C (en) * 1988-09-01 1994-03-29 Shigenori Tanaka Horseshoe crab amebocyte lysate factor g inhibitor
DE69002657T2 (de) * 1989-02-06 1994-03-24 Den Ichi Mizuno Limulustest-positives Pflanzenglykolipid und Verfahren zur Stimulierung des Immunsystems eines Tieres.

Also Published As

Publication number Publication date
EP0561408A1 (de) 1993-09-22
US5424300A (en) 1995-06-13
JPH05262654A (ja) 1993-10-12
KR930019219A (ko) 1993-10-18
EP0561408B1 (de) 1996-06-26
DE69303305D1 (de) 1996-08-01
DE69303305T2 (de) 1997-02-06
CA2091866A1 (en) 1993-09-19

Similar Documents

Publication Publication Date Title
ATE364386T1 (de) (s,s)-reboxetine zur behandlung von chronischen erschöpfungssyndrom
DE58905201D1 (de) Mittel zur behandlung des parkinson-syndroms.
NO982311L (no) Sammensetninger og fremgangsmÕter for forhindring og behandling av oral muscositt
PT971713E (pt) Utilizacao de inibidores da colinesterase para tratamento de desordens da atencao
DE69530926D1 (de) Mittel zur förderung des haarwachstums
DK1187603T3 (da) Kombinationsterapi tl at bevirke vægttab og at behandle obesitet
DE60133029D1 (de) Mittel zur prävention oder behandlung von psoriasi
BR0207961A (pt) Combinação de análogos da epotilona e agentes quimioterápicos para o tratamento de doenças proliferativas
TR200103576T2 (tr) Üre ikameli/katkılı imidazokinolinler.
PT1202724E (pt) Metodo para tratamento da dor cronica utilizando inibidores mek
AU1565300A (en) Anti-germinating method for tubers and bulbs using eugenol and/or isoeugenol
DE69932510D1 (de) Vaskularisierungsinhibitoren
ES2140670T3 (es) Cicatrizacion de heridas.
SE9304098L (sv) Anordning för fallskyddad klättring
ATE139698T1 (de) Mittel zur behandlung chronischer ermüdungserscheinungen
DE69906568D1 (de) Behandlung von hämorrhagischem virusfieber mit protein c
DE69231384D1 (de) Zusammensetzungen zur behandlung des chronischen erschöpfungs-syndroms
DE69327812D1 (de) Arsen-enthaltende arzneimittel zur behandlung des chronischen ermüdungssyndroms
DE69011871D1 (de) In-line-geräuschdämpfungsvorrichtung.
EE200300213A (et) SARP-1 kasutamine sklerodermia raviks ja/või ennetamiseks
RU94041028A (ru) Применение производных мелатонина для лечения десинхронизационных нарушений, фармацевтическая композиция
ES2058451T3 (es) Un metodo para la preparacion de una composicion farmaceutica.
ID27052A (id) Pengobatan arthritis dan keadaan-keadaan lain yang sekupa
DE60039122D1 (de) 6-o-alkyl-2-nor-2-substituierte ketolidderivate
EP1406605A4 (de) Carbamate von 2-heterozyklischen 1,2-ethandiolen